Phase III trials

Rosen Law Firm notifies $RARE investors of securities class action alleging materially false statements about setrusumab efficacy in Phase III trials, with April 6, 2026 lead plaintiff deadline.

Rosen Law Firm files securities class action against Ultragenyx Pharmaceutical ($RARE) alleging false statements about setrusumab efficacy in clinical trials.

Securities class action filed against RARE over alleged false statements regarding Phase III clinical trials for setrusumab. Claim deadline April 6, 2026.

Ultragenyx faces a securities class action alleging misrepresentations about its setrusumab drug's efficacy for osteogenesis imperfecta. Affected investors have until April 6, 2026 to serve as lead plaintiff.

Ultragenyx faces securities lawsuit alleging false claims about drug setrusumab for bone disease. Investors have until April 6, 2026 deadline to join class action.

Rosen Law Firm sues Ultragenyx for securities fraud, alleging executives misrepresented drug efficacy. Investors who bought stock August 2023-December 2025 can claim damages by April 6, 2026 deadline.

Ultragenyx faces securities lawsuit alleging misleading claims about setrusumab's efficacy. Investors must act by April 6, 2026 deadline to join class action.